Identification of Novel Genes and Associated Drugs in Cervical Cancer by Bioinformatics Methods

16 April 2022 : Database Analysis

Dan Wang^1CDE, Yanling Liu^2F, Shuyu Cheng^1D, Guoyan Liu^123AG*

DOI: 10.12659/MSM.934799

Med Sci Monit 2022; 28:e934799

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 The significant drugs targeted to AURKA.

Drug ID	Drug name	Drug group	Confidence score
DB12010	Fostamatinib	Approved; Investigational	1
DB08896	Regorafenib	Approved	0.4247
DB01254	Dasatinib	Approved; Investigational	0.4221
DB12267	Brigatinib	Approved; Investigational	0.3649
DB08901	Ponatinib	Approved; Investigational	0.3572
DB06589	Pazopanib	Approved	0.3339
DB00398	Sorafenib	Approved; Investigational	0.3319
DB00619	Imatinib	Approved	0.3291
DB09079	Nintedanib	Approved	0.3128
DB00945	Acetylsalicylic acid	Approved; Vet approved	0.3053
DB01268	Sunitinib	Approved; Investigational	0.2983
DB06616	Bosutinib	Approved	0.279
DB00675	Tamoxifen	Approved	0.2778
DB08912	Dabrafenib	Approved; Investigational	0.2668
DB05294	Vandetanib	Approved	0.2632
DB09078	Lenvatinib	Approved; Investigational	0.2557
DB08875	Cabozantinib	Approved; Investigational	0.2384
DB11817	Baricitinib	Approved; Investigational	0.2319
DB06626	Axitinib	Approved; Investigational	0.2307
DB08895	Tofacitinib	Approved; Investigational	0.2201
DB06595	Midostaurin	Approved; Investigational	0.2168

Back to the Article